Journal of Viral Hepatitis最新文献

{"title":"Protective Role of Coffee in Chronic Liver Disease: A Focus on Processing","authors":"Rofida Khalifa,&nbsp;Khalid Al-Naamani,&nbsp;Mohamed Elbadry,&nbsp;Yuan-Yuan Zhang,&nbsp;Khalid Alswat,&nbsp;Mohamed El-Kassas","doi":"10.1111/jvh.70072","DOIUrl":"https://doi.org/10.1111/jvh.70072","url":null,"abstract":"<div>\u0000 \u0000 <p>Chronic liver disease (CLD) is a leading cause of global morbidity and mortality, necessitating effective preventive strategies. Growing evidence is linking coffee consumption with reduced risk of disease progression in various CLDs, including metabolic dysfunction associated steatotic liver disease (MASLD), alcoholic liver disease, hepatitis B and C, autoimmune hepatitis, and a reduction in the risk of hepatocellular carcinoma development. Coffee, a globally consumed beverage, contains bioactive compounds like caffeine, chlorogenic acids, diterpenes, and polyphenols, which may offer hepatoprotective benefits through anti-inflammatory, antioxidant, and metabolic regulatory effects. This narrative review discusses the current evidence demonstrating an inverse correlation between regular coffee intake and CLD progression, highlighting dose-dependent benefits with optimal consumption at three to four cups per day. Potential mechanisms for hepatoprotective effects of coffee involve modulation of the gut-liver axis, epigenetic regulation, and improving liver transaminitis. Additionally, the current review explores the effects of different coffee processing methods, such as roasting levels and brewing techniques, on these protective properties. Coffee's role as an affordable, culturally accepted intervention to mitigate the burden of CLD offers a compelling avenue for future public health strategies. Despite promising evidence, there is a need for further proof to establish the most beneficial coffee preparation methods.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145012209","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in Use of Direct-Acting Antivirals for Treatment of Hepatitis C Virus Infection in Australia 2016–2024","authors":"Chieu-Hoang Ly Luong,&nbsp;Lisa Kalisch Ellett,&nbsp;Nicole Pratt,&nbsp;Kirsten Staff,&nbsp;Jack Janetzki","doi":"10.1111/jvh.70082","DOIUrl":"https://doi.org/10.1111/jvh.70082","url":null,"abstract":"<p>Direct-acting antivirals (DAAs) have transformed hepatitis C virus (HCV) treatment in Australia since their inclusion on the Pharmaceutical Benefits Scheme (PBS) in 2016. Treatment has shifted from genotype-specific to pan-genotypic regimens, with glecaprevir/pibrentasvir and sofosbuvir/velpatasvir now recommended in clinical guidelines. This study examined trends in DAA dispensing in light of evolving treatment regimens. A retrospective analysis of publicly available PBS data was conducted, assessing monthly DAA dispensings from March 2016 to December 2024. Dispensings were summarised by count and proportion, PBS item code, schedule (general, private, or public hospital) and number of repeats as a proxy for treatment duration. Dispensing volumes of DAAs increased following PBS-listing in March 2016, with the highest number of dispensings observed between 2016 and 2017 (average of 11,378 prescriptions dispensed per month). Dispensing rates subsequently declined, with an average of 1583 prescriptions dispensed per month from 2020 to 2024. Since introduction to market in August 2017, sofosbuvir with velpatasvir (pan-genotypic regimen) has maintained an average market share of 55%. Glecaprevir/pibrentasvir (pan-genotypic regimen) has maintained an average market share of 34% since its introduction in August 2018. Sofosbuvir/velpatasvir/voxilaprevir, listed on the PBS in April 2019, and used for salvage therapy, has had a smaller average market share of 4% since listing. Pan-genotypic regimens now account for nearly all DAA use in Australia. Declining dispensing rates may reflect reduced new infections and treatment fatigue. Increasing retreatment rates underscore the need for ongoing monitoring and real-world evaluations. Future head-to-head comparisons may support optimal regimen selection.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70082","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144998713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Demographic and Clinical Characteristics of Patients With Hepatitis C and Hepatitis B Co-Infection, Georgia, 2017–2023","authors":"Senad Handanagic,&nbsp;Shaun Shadaker,&nbsp;Davit BaliashvilI,&nbsp;Irina Tskhomelidze Schumacher,&nbsp;Paige A. Armstrong,&nbsp;Rania A. Tohme,&nbsp;Maia Butsashvili","doi":"10.1111/jvh.70067","DOIUrl":"https://doi.org/10.1111/jvh.70067","url":null,"abstract":"<div>\u0000 \u0000 <p>Persons co-infected with hepatitis C virus and hepatitis B virus (HCV-HBV) are at increased risk of developing liver disease compared with mono-infected individuals. In Georgia, all patients undergoing hepatitis C treatment are eligible for free testing for hepatitis B surface antigen (HBsAg). However, further hepatitis B evaluations and treatment are not free. We explored demographic and clinical characteristics associated with HCV-HBV co-infection among persons treated for HCV infection. Persons aged ≥ 18 years with HCV infection who initiated HCV treatment during 2017–2023 were included. Patients were grouped as HCV mono-infected, HCV-HBV co-infected (HBsAg positive), and HBV exposed (total HBV core antibody positive, HBsAg negative). We present descriptive analysis and adjusted prevalence ratios (aPR) with 95% confidence intervals (95% CI). Of 54,994 adults treated for hepatitis C, 68.1% had HCV mono-infection, 29.3% were previously exposed to HBV, and 2.6% had HCV-HBV co-infection. Persons who were aged 18–45 years (aPR: 1.75, 95% CI: 1.48–2.08), male (aPR: 1.38, 95% CI: 1.11–1.71), reported ever injecting drugs (aPR: 1.40, 95% CI: 1.19–1.66), had end-of-HCV treatment, alanine transaminase (ALT) levels &gt; 80 IU/L (aPR: 2.14, 95% CI: 1.40–3.29) and did not achieve hepatitis C cure after treatment (aPR: 1.83, 95% CI: 1.13–2.95) were more likely to have HCV-HBV co-infection vs. HCV mono-infection. Patients who did not achieve cure and had persistently higher ALT levels after hepatitis C treatment were more likely to have HCV-HBV co-infection. Expanded access to hepatitis B care and treatment, and co-management of HBV infection along with HCV treatment in co-infected persons are needed to improve clinical outcomes.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Trends and Health Inequalities in Acute Hepatitis E Burden: A Joinpoint Regression and Cross-Country Inequality Analysis, 1990–2021","authors":"Deliang Huang,&nbsp;Zhibin Zhu,&nbsp;Jinghan Peng,&nbsp;Siyu Zhang,&nbsp;Yuanyuan Chen,&nbsp;Jinyan Jiang,&nbsp;Huiyi Lai,&nbsp;Hong Yu,&nbsp;Qi Zhao,&nbsp;Yanping Chen,&nbsp;Jun Chen","doi":"10.1111/jvh.70073","DOIUrl":"https://doi.org/10.1111/jvh.70073","url":null,"abstract":"<div>\u0000 \u0000 <p>Acute hepatitis E (AHE) disproportionately affects regions with diverse socioeconomic conditions. This study aims to assess the trends in AHE burden and health inequalities from 1990 to 2021. Utilising data from the Global Burden of Disease 2021, joinpoint regression was employed to identify significant trends. Cross-country inequality analysis was conducted to quantify the distributive inequalities in the burden of AHE. The trends of AHE incidence, prevalence, deaths and disability-adjusted life years (DALYs) rate have experienced a marked decrease from 1990 to 2021, reaching the lowest recorded in 2021. However, the numbers of those continued to increase. An inverse relationship was found between AHE disease rate and sociodemographic index (SDI) levels. The joinpoint regression analysis confirmed a downward trend of AHE globally and in the five SDI levels. Notably, incidence and prevalence rates in high-middle SDI increased from 2015, while those in high SDI slowed down from 2001. Mortality and DALYs rates showed a deceleration in high-middle SDI and a rebound in high SDI from 2009 to 2021. Cross-country inequality analysis disclosed that lower SDI countries disproportionately bear a higher AHE burden, with the magnitude of these inequalities decreasing over time. The study uncovered an inverse correlation between the AHE disease rate and SDI level. Despite a consistent decline in hepatitis E virus disease rate across the five SDI levels, the disparity in burden persists, with developing regions retaining a relatively elevated load. Meanwhile, developed regions exhibit a resurgence, characterised by an upward trend. This dynamic epidemiological shift underscores the ongoing need for vigilant monitoring and adaptable approaches in the management of the disease.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934749","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Early Read-Time Performance of the OraQuick HCV Rapid Antibody Assay for the Exclusion of HCV Viremia","authors":"Jessie Torgersen,&nbsp;David Smookler,&nbsp;Rebecca Russell,&nbsp;Julia Gasior,&nbsp;Dean M. Carbonari,&nbsp;Nancy Aitcheson,&nbsp;Camelia Capraru,&nbsp;Bettina Hansen,&nbsp;Jordan J. Feld,&nbsp;Vincent Lo Re III","doi":"10.1111/jvh.70066","DOIUrl":"https://doi.org/10.1111/jvh.70066","url":null,"abstract":"<div>\u0000 \u0000 <p>Rapid point-of-care tests for hepatitis C virus (HCV) provide results in 20 min and allow linkage to care, particularly for difficult-to-reach populations. Prior work suggested an early reading time of the OraQuick (OQ) rapid HCV antibody lateral flow immunoassay identified people with HCV viremia; however, these observations were not externally validated. We conducted a prospective cohort study at Penn Presbyterian Medical Center from June 2021 to August 2023 to evaluate the performance of OQ early reading times for HCV viremia among participants with reactive HCV antibody. Following test device insertion for whole blood substrate, the OQ assay was evaluated every minute from 5 to 10 min, then at 20 and 40 min. Early read time performance was evaluated against the standard of care HCV RNA. 175 participants (120 [68.6%] with detectable HCV viremia) completed the OQ assay. Among HCV viremic participants, 119 had a positive whole blood OQ by 7 min (sensitivity: 99.2% [95% confidence interval, CI: 95.4–100]; positive predictive value: 82.1% [95% CI: 74.8–87.9]); 1 viremic participant with severe immunosuppression was not identified at this early reading time. No time interval accurately identified only those with HCV viremia, yet a negative OQ test at 7 min excluded HCV viremia (negative predictive value: 96.3% [95% CI: 81.0–99.9]). A 7-min reading time for a whole blood OQ assay may reduce the need for HCV RNA testing and improve screening efficiency by identifying people without HCV viremia. Early read time results cannot be used to exclusively identify HCV viremia and should be used with caution in those with severe immunosuppression or if acute HCV infection is suspected.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144934748","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Factors for Hepatitis C Virus Among the General Population in Sub-Saharan Africa—An Analysis of Systematic Review Data","authors":"Getahun Molla Kassa,&nbsp;Aaron G. Lim,&nbsp;Melaku Tileku Tamiru,&nbsp;Tesfa Sewunet Alamneh,&nbsp;Peter Vickerman,&nbsp;Emebet Dagne,&nbsp;Andargachew Mulu,&nbsp;Obsie Baissa,&nbsp;Ora Paltiel,&nbsp;John F. Dillon,&nbsp;Elias Ali Yesuf,&nbsp;Matthew Hickman,&nbsp;Josephine G. Walker,&nbsp;Clare E. French,&nbsp;DESTINE NIHR Global Health Research Group","doi":"10.1111/jvh.70065","DOIUrl":"https://doi.org/10.1111/jvh.70065","url":null,"abstract":"<p>Understanding risk factors for hepatitis C virus (HCV) is critical for targeting screening and prevention. We systematically reviewed risk factors associated with HCV seroprevalence among the general population in sub-Saharan Africa (SSA). Comprehensive systematic review of HCV seroprevalence of community-based observational studies reporting HCV risk factors in SSA. Study quality was assessed using Joanna Briggs Institute tool. Random effect meta-analyses were used to estimate odds ratios (OR) with 95% confidence intervals (CI). We identified 92 studies. Higher odds of HCV seroprevalence were observed among age 21–64 (OR = 1.77, 95% CI 1.17–2.68) and 65+ groups (OR = 11.75, 95% CI 5.51–25.05) compared to those aged ≤ 20 years; not being formally educated (OR = 1.78, 95% CI 1.35–2.35) compared to secondary/above and being married (OR = 1.91, 95% CI 1.45–2.51) or divorced (OR = 3.20, 95% CI 1.91–5.36) compared to never married. Family history of HCV (OR = 1.52, 95% CI 1.17–1.96), being a person living with HIV (OR = 2.64, 95% CI 1.61–4.33) or being HBsAg positive (OR = 1.66, 95% CI 1.10–2.50) were all positively associated with increased HCV seroprevalence, as was having a history of blood transfusion (OR = 1.81, 95% CI 1.33–2.45), hospitalisation (OR = 1.55, 95% CI 1.22–1.96), medical operation (OR = 1.28, 95% CI 1.01–1.62), scarification (OR = 1.29, 95% CI 1.01–1.64) and injection drug use (OR = 7.04, 95% CI 1.16–42.68). Pilot HCV screening programmes targeting older adults and people exposed to healthcare-associated factors could potentially lead to the efficient detection of HCV cases and reduce future HCV exposures among the general population in SSA countries.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 10","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70065","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144923763","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Global Systematic Review of the Measurement of Stigma Associated With People Living With Hepatitis B or Hepatitis C Viruses","authors":"Freddy Green,&nbsp;Ruth Simmons,&nbsp;David Leeman,&nbsp;Monica Desai,&nbsp;Matthew Hibbert","doi":"10.1111/jvh.70064","DOIUrl":"https://doi.org/10.1111/jvh.70064","url":null,"abstract":"<p>Chronic hepatitis B and C affect over 300 million people globally. Despite treatment advances, stigma towards people living with hepatitis B/C (PLWHB/C) remains a barrier to care and impacts health outcomes. Addressing this stigma is key to achieving hepatitis elimination goals. This systematic review aims to synthesise existing approaches to measuring stigma experienced by PLWHB/C and examine factors associated with stigma in different social contexts. Databases searched included PubMed, PsycInfo and Web of Science, as well as grey literature (01/01/2008–30/06/2023). Studies were included if stigma experienced by or directed towards PLWHB/C was measured quantitatively. Data from included studies were synthesised using a narrative approach. Among 3053 studies, 81 were included. Various tools were used to measure internalised (e.g., self-blame, shame), enacted (e.g., experiences of discrimination) and anticipated stigma (e.g., expectations of discrimination) related to PLWHB/C; most commonly the Toronto Chinese Hepatitis B Stigma Scale and Brener and Von Hippel's tool. Stigma was highly prevalent, impacting psychosocial wellbeing, treatment-seeking behaviours and quality of life. Lower knowledge and conservative beliefs were linked to higher public stigma. Educational interventions and stigma-reducing media showed some benefit in mitigating stigmatising attitudes. The review highlights stigma's pervasive nature and detrimental psychosocial impacts for PLWHB/C globally. While diverse measurement tools were used, standardising culturally validated instruments aligned with conceptual frameworks could improve research. Tailored educational initiatives could help reduce stigmatising attitudes. Crucially, stigma hindered timely diagnosis and treatment access, emphasising the need for multi-level interventions addressing stigma to achieve elimination goals.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 9","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-08-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70064","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144897783","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HCV Screening Before Endoscopy in Hepatogastroenterology Outpatient Clinic: The Depist C Endo Study","authors":"André-Jean Remy,&nbsp;Serge Bellon,&nbsp;Ryad Smadhi,&nbsp;Jacques Bottlaender,&nbsp;Isabelle Rosa,&nbsp;Mathias Vidon,&nbsp;Florent Ehrhard,&nbsp;Guillaume Conroy,&nbsp;Armand Garioud","doi":"10.1111/jvh.70063","DOIUrl":"https://doi.org/10.1111/jvh.70063","url":null,"abstract":"<div>\u0000 \u0000 <p>Systematic screening for hepatitis C virus (HCV) by serology once in a lifetime is recommended by the French Association for the Study of the Liver, but not by the French National Authority for Health. Screening focused on subjects aged over 40 years would seem more appropriate, as the prevalence of hepatitis C increases with age. The aim of this study was to assess the feasibility (number of serologies proposed) and acceptability (number of serologies performed) of HCV screening prior to endoscopy in people aged 40 years and over seen in gastroenterology consultations in non-university hospitals; and to determine whether the prevalence after age 40 is higher than in the general population (0.86%). As of 1 June 2023, 490 patients were included in eight different hospitals in six regions of metropolitan France; 97.4% of patients accepted the prescription of HCV serology and 97.6% of prescribed serologies were performed; 55.5% were men and 44.4% women with a mean age of 58 years (range, 40–90). The HCV serology positivity rate was 6% (29 patients). No previous HCV serology was known. Risk exposures associated with positive HCV serology were drug use in 19 patients, a history of transfusion in six patients and origin from an endemic country in five patients; 90% of positive serologies concerned men and the mean age was 65 years (range, 49–85). Mean hepatic elastometry was 8.7 kPa; 11 out of 28 patients tested had a positive HCV viral load and were treated. Systematic screening for hepatitis C after the age of 40 years and before digestive endoscopy is feasible, well accepted and enables a high number of patients to be managed.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 9","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-08-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144869919","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Treatment Discontinuation and Adherence in Patients With Chronic Hepatitis B Infection Newly Initiating Nucleos(t)ide Analogues in Japan: A Retrospective Cohort Study","authors":"Shinya Kawamatsu,&nbsp;Kiran K. Rai,&nbsp;Vera Gielen,&nbsp;Amisha Patel,&nbsp;Olivia Massey,&nbsp;Seth W. Anderson,&nbsp;Yutaka Handa,&nbsp;Ethan Yichen Lee,&nbsp;Poppy Payne,&nbsp;Isabel Jimenez,&nbsp;Kejsi Begaj,&nbsp;Shayon Salehi,&nbsp;Jun Inoue,&nbsp;Afisi S. Ismaila","doi":"10.1111/jvh.70062","DOIUrl":"https://doi.org/10.1111/jvh.70062","url":null,"abstract":"<p>Nucleos(t)ide analogue (NA) therapy is the current standard of care for chronic hepatitis B (CHB) virus infection but rarely achieves functional cure, necessitating long-term therapy, which often leads to nonadherence and increased treatment burden. This retrospective cohort study was designed to describe treatment discontinuation and adherence to second-generation NAs among patients with CHB in Japan. We used the Japanese Medical Data Center Claims Database (JMDC Inc.) to identify adults with CHB who were newly initiated on a single-agent, second-generation NA between January 2007 and August 2023. Outcomes included treatment discontinuation and adherence, treatment restart after discontinuation, NA switching and factors associated with treatment discontinuation/adherence. Of the 2473 patients included in this study (mean age 49.9 years), 65.6% were male. The most common index NAs were entecavir (55.5%) and tenofovir alafenamide fumarate (TAF, 36.2%). Treatment discontinuation was observed in 20.3% of patients; mean time to discontinuation was 20.4 months. Of the patients who discontinued, 50.7% restarted NAs. Mean adherence (proportion of days covered [PDC]) was 0.87, and 81.2% of participants had PDC ≥ 80%. Age group 35–64 years, index treatment TAF and baseline hepatocellular carcinoma diagnosis were significantly associated with a decreased probability of treatment discontinuation and nonadherence. Although a high proportion of patients were persistent and adherent to NA treatment, there is a subgroup of patients whose needs are not met while receiving NA treatment, particularly in younger age groups. The results emphasise the need for alternative therapies with shorter, finite treatment durations to improve patient persistence, adherence and outcomes.</p>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 9","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-08-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jvh.70062","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144833233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Observational Study on HBV Reactivation After Direct-Acting Antiviral Therapy in HCV/HBV Coinfected Patients in Guizhou, China","authors":"Mei Wang,&nbsp;Yi Wang,&nbsp;Zhigang Yang,&nbsp;Changming Yang,&nbsp;Jing Wang,&nbsp;Huagang Xiong","doi":"10.1111/jvh.70061","DOIUrl":"https://doi.org/10.1111/jvh.70061","url":null,"abstract":"<div>\u0000 \u0000 <p>The objective of this study is to analyse the prevalence and clinical characteristics of HCV/HBV coinfection in Guizhou, and evaluate the rate of HBV reactivation during and after anti-HCV treatment in a real-world study. This retrospective study included 1652 patients with hepatitis C virus (HCV) infection who received direct-acting antiviral (DAA) therapy at the Guiyang Public Health Clinical Center between January 2018 and December 2022 Baseline, on-treatment and posttreatment data were collected, including HCV RNA, HCV genotypes, liver function, hepatitis B virus (HBV) markers (HBsAg, HBcAb) and HBV DNA levels. The HCV/HBV coinfection rate was analysed, and the risk of HBV reactivation and disease progression following DAA therapy was assessed. Among the 1652 HCV-infected patients, the HCV/HBV coinfection rate was 49.88% (824/1652). Of these, 5.08% (84/1652) were HBsAg-positive, while 44.79% (740/1652) were HBsAg-negative/HBcAb-positive with HBV DNA &lt; 20 IU/mL. Compared to patients with HCV monoinfection, HBsAg-positive patients had a higher proportion of males, compensated and decompensated cirrhosis, hepatocellular carcinoma (HCC) and lower platelet (PLT) counts (<i>χ</i>² = 15.482, 46.101; <i>F</i> = 7.292; all <i>p</i> &lt; 0.05). Differences in HCV genotype distribution were observed among various HBV immune status groups (<i>χ</i>² = 32.529, <i>p</i> &lt; 0.05). The cumulative incidence of HBV reactivation in HCV/HBV coinfected patients treated with DAAs was 1.2% (10/824). Among these, the reactivation rate was 16.67% (9/54) in HBsAg-positive patients without prophylactic anti-HBV therapy and 0.1% (1/740) in HBsAg-negative/HBcAb-positive patients. Baseline HBsAg levels were significantly higher in patients with HBV reactivation than in those without reactivation (<i>Z</i> = −4.291, <i>p</i> &lt; 0.05). No significant changes were observed in liver function or PLT levels after HBV reactivation compared to baseline (<i>p</i> &gt; 0.05), and no cases of liver failure were reported. In Guizhou, a relatively high prevalence of HBsAg-positivity and a large proportion of past HBV exposure (HBsAg-negative/HBcAb-positive, HBV DNA &lt; 20 IU/mL) were observed among HCV-infected patients. While HBV reactivation can occur in HCV/HBV coinfected patients undergoing DAA therapy, the overall risk is low. A baseline HBsAg level &gt; 185 IU/mL is a significant risk factor for HBV reactivation.</p>\u0000 </div>","PeriodicalId":17762,"journal":{"name":"Journal of Viral Hepatitis","volume":"32 9","pages":""},"PeriodicalIF":2.3,"publicationDate":"2025-08-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144782728","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}